The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.
Patient age ≥18 years;
Acute ischemic stroke patient confirmed by imaging;
Time of onset: within 3 months;
Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
MRI contraindication;
Hemorrhagic transformation after acute Ischemic stroke;
Contraindication for antiplatelet or anticoagulation therapy;
Severe head trauma or intracranial hemorrhage occurred in the past six months;